Incorporated as a private limited company in Jul.'87, Shilpax Laboratories (SLL) was converted to a public limited company in Aug.'92. It was promoted by R P Singhal and Meera Singhal but was taken over by the Paam group. It is currently managed by chairman Arvind Bhargava. Other companies under the Paam group are Paam Pharmaceuticals (Delhi), Paam Eatables, Paam Antibiotics, etc. The company's existing plant at Surajpur Industrial Area (Ghaziabad district), Uttar Pradesh, produces basic drugs. In Feb.'94, the company came out with a public issue at par, aggregating Rs 3.63 cr, to part-finance a Rs 5.21-cr project at Ghaziabad, Uttar Pradesh, to manufacture bulk drugs and to meet working capital requirements. The facilities for bulk drugs has been put up at the site adjacent to the existing location. The capacity of the new plant is 48 tpa for ampicillin trihydrate, 30 tpa for amoxycillin trihydrate, 30 tpa for ampicilin sodium crystalline, 73 tpa for ampi-dane salt and 27 tpa for amoxy-dane salt. These are bacterial broad-spectrum antibiotics and are used in the treatment of various infections of the respiratory tract, urinary tract, GI tract, ENT diseases, venereal diseases and in the treatment of surgical infections. SLL exports bulk drugs to countries in east Europe, Latin America and the CIS. Company is planning to set-up a new Bulk Drug Unit at Tapukara, Rajasthan, for which company has filed Memorandum to Secretariat of Industrial Approvals. Since the market of domestic pharmaceutical industries has shrunk substantially resulting in squeezed margins and nose-diving performance of the Indian Companies, the company also has suffered a loss of Rs.137.39 lacs during the year 1999-2000.